Literature DB >> 24381395

Steroid-resistant nephrotic syndrome secondary to primary focal segmental glomerulosclerosis and smoldering multiple myeloma.

Rupin Shah1, Nishi Shah1, Arun Shah1, Ankit N Mehta1.   

Abstract

We present a patient with steroid-resistant nephrotic syndrome due to focal segmental glomerulosclerosis along with smoldering multiple myeloma. While investigating the cause of proteinuria, a monoclonal gammopathy with a negative kidney biopsy for myeloma-related pathology was discovered.

Entities:  

Year:  2014        PMID： 24381395      PMCID： PMC3862124          DOI： 10.1080/08998280.2014.11929039

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


  8 in total

Review 1.  Focal and segmental glomerulosclerosis and plasma cell proliferative disorders.

Authors:  David Dingli; Dirk R Larson; Matthew F Plevak; Joseph P Grande; Robert A Kyle
Journal:  Am J Kidney Dis       Date:  2005-08       Impact factor: 8.860

Review 2.  Treatment of primary FSGS in adults.

Authors:  Stephen M Korbet
Journal:  J Am Soc Nephrol       Date:  2012-09-20       Impact factor: 10.121

3.  Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.

Authors:  Glen S Markowitz; Gerald B Appel; Paul L Fine; Andrew Z Fenves; Nicholas R Loon; Sundar Jagannath; Joseph A Kuhn; Adam D Dratch; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2001-06       Impact factor: 10.121

4.  Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.

Authors:  Samih H Nasr; Anthony M Valeri; Sanjeev Sethi; Mary E Fidler; Lynn D Cornell; Morie A Gertz; Martha Lacy; Angela Dispenzieri; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  Am J Kidney Dis       Date:  2012-03-13       Impact factor: 8.860

Review 5.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

Review 6.  Treatment of multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2011-04-26       Impact factor: 66.675

Review 7.  Early versus deferred treatment for early stage multiple myeloma.

Authors:  Y He; K Wheatley; O Clark; A Glasmacher; H Ross; B Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2003

8.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245
  8 in total
  2 in total

1.  Multiple myeloma with a previous diagnosis of focal segmental glomerulosclerosis: A case report and review of the literature.

Authors:  Zhe-Yi Dong; Hai-Tao Xing; Yuan-DA Wang; Wei Zhang; Qiang Qiu; Xiang-Mei Chen
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

2.  Podocytopathy in patients with monoclonal gammopathy: three patients and literature review.

Authors:  Andrés Ribas; Adrián Puche; Javier Gimeno; Laia Sans; Clara Barrios; Eva Márquez; Dolores Naranjo; Belén Lloveras; Joan Lop; Natàlia Ramos; Maria José Soler; Alejandra Gabaldon; Marta Crespo; Eva Rodríguez
Journal:  Clin Kidney J       Date:  2021-09-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.